Karyopharm Therapeutics Inc. Insider Trading Activity

Karyopharm Therapeutics EVP & Chief Medical Officer Reshma Rangwala reported routine equity compensation activity.

Rhea-AI Filing Summary

Karyopharm Therapeutics EVP & Chief Medical Officer Reshma Rangwala reported routine equity compensation activity. On May 13, she acquired 947 shares of common stock at no cost from performance-based restricted stock units that vested after certification of a Phase 3 XPORT-EC-042 enrollment milestone. On May 14, 408 shares were sold at $9.50 per share under a durable automatic sale instruction plan adopted on April 4, 2022, solely to cover withholding tax obligations upon PSU vesting. Following these transactions, she directly holds 56,829 shares of common stock.

Insider Trade Summary

Net Seller: 408 shares

Net Sell 2 txns

Insider Rangwala Reshma

Role EVP & Chief Medical Officer

Sold 408 shs ($4K)

Type	Security	Shares	Price	Value
Sale	Common Stock	408	$9.50	$4K
Grant/Award	Common Stock	947	$0.00	$0.00

Holdings After Transaction: Common Stock — 56,829 shares (Direct)

Footnotes (2)

1. F1. Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on May 13, 2026.
2. F2. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.

Key Figures

Shares acquired from PSUs: 947 shares Shares sold for taxes: 408 shares Sale price: $9.50 per share +3 more

6 metrics

Shares acquired from PSUs 947 shares Performance-based RSUs vested on May 13, 2026

Shares sold for taxes 408 shares Open-market sale on May 14, 2026 for tax withholding

Sale price $9.50 per share Broker-assisted sale to satisfy withholding taxes

Shares held after transactions 56,829 shares Direct ownership following award and tax-related sale

PSU grant timing February 2024 Performance-based RSUs that vested upon milestone achievement

Plan adoption date April 4, 2022 Durable automatic sale instruction plan for tax sales

Key Terms

performance-based restricted stock units, PSUs, Phase 3 XPORT-EC-042 trial, Compensation Committee, +2 more

6 terms

performance-based restricted stock units financial

"Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024"

Performance-based restricted stock units are a type of employee equity award that converts into company shares only if predefined financial or operational targets are met over a set period. Think of it like a bonus check that becomes stock only when specific goals are hit; it ties pay to results, aligning managers’ incentives with shareholders. Investors care because these awards affect future share count, executive incentives, and signal how management’s success will be measured and rewarded.

PSUs financial

"Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting"

PSUs are company shares promised to employees or executives that only become actual stock if the business hits specific performance targets over a set period. For investors, PSUs matter because they link pay to measurable outcomes — similar to a conditional bonus that converts into ownership — which can influence management decisions, dilution of shares, and signals about confidence in future results.

Phase 3 XPORT-EC-042 trial technical

"based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial"

Compensation Committee financial

"as certified by the issuer's Compensation Committee on May 13, 2026"

A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.

durable automatic sale instruction plan financial

"This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022"

withholding tax liability financial

"represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Karyopharm (KPTI) report for Reshma Rangwala?

Karyopharm reported that EVP & Chief Medical Officer Reshma Rangwala received 947 common shares from vested performance-based RSUs, then sold 408 shares at $9.50 each in a broker-assisted sale to cover withholding taxes related to the vesting.

Was the Karyopharm (KPTI) insider sale by Reshma Rangwala discretionary?

The 408-share sale by Reshma Rangwala was not discretionary. It was executed under a durable automatic sale instruction plan adopted April 4, 2022, specifically to satisfy withholding tax liabilities from vested performance-based restricted stock units.

How many Karyopharm (KPTI) shares does Reshma Rangwala hold after these transactions?

After the reported transactions, EVP & Chief Medical Officer Reshma Rangwala directly holds 56,829 shares of Karyopharm common stock. This reflects the vesting of 947 performance-based RSUs and the automatic sale of 408 shares to cover associated tax obligations.

What triggered the PSU vesting for Karyopharm (KPTI) insider Reshma Rangwala?

The PSUs vested after Karyopharm’s Compensation Committee certified achievement of a clinical milestone: complete enrollment in the Phase 3 XPORT-EC-042 trial. Each earned performance-based restricted stock unit delivered one share of common stock upon vesting on May 13, 2026.

At what price were Karyopharm (KPTI) shares sold in the insider tax sale?

The 408 Karyopharm common shares associated with the tax-related transaction were sold at $9.50 per share. This broker-assisted sale was executed solely to cover withholding tax liabilities following vesting of performance-based restricted stock units.

What type of equity award did the Karyopharm (KPTI) insider receive?

Reshma Rangwala received shares underlying performance-based restricted stock units granted in February 2024. These PSUs were earned based on achieving the Phase 3 XPORT-EC-042 enrollment milestone and vested on May 13, 2026, delivering 947 shares of common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:07 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rangwala Reshma

(Last) (First) (Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON MASSACHUSETTS 02459

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/13/2026		A		947(1)	A	$0.0	57,237	D
Common Stock	05/14/2026		S(2)		408	D	$9.5	56,829	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on May 13, 2026.

2. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.

	/s/ Nancy Smith as Attorney-in-Fact for Reshma Rangwala	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)